克林沙星的药代动力学和炎性液体渗透情况
Pharmacokinetics and inflammatory fluid penetration of clinafloxacin.
作者信息
Wise R, Jones S, Das I, Andrews J M
机构信息
Department of Microbiology, City Hospital NHS Trust, Birmingham, United Kingdom.
出版信息
Antimicrob Agents Chemother. 1998 Feb;42(2):428-30. doi: 10.1128/AAC.42.2.428.
Abstract
A single 200-mg dose of clinafloxacin was given orally to each of nine healthy male volunteers, and the concentrations of the drug were measured in plasma, cantharidin-induced inflammatory fluid, and urine over the following 24 h (48 h in the case of urine). The mean maximum concentration in plasma was 1.34 microg/ml at a mean time of 1.8 h postdose. The mean maximum concentration in the inflammatory fluid was 1.3 microg/ml at 3.8 h postdose. The mean elimination half-life of clinafloxacin in plasma was 5.65 h. The overall penetration into the inflammatory fluid was 93.1%, as assessed by determining the ratio of area under the concentration-time curves. Recovery of clinafloxacin in urine was 58.8% by 24 h and 71.8% by 48 h postdose.
摘要
给9名健康男性志愿者每人口服200毫克单剂量的克林沙星，然后在接下来的24小时内（尿液情况为48小时）测量血浆、斑蝥素诱导的炎性液体和尿液中的药物浓度。血浆中的平均最大浓度在给药后1.8小时时为1.34微克/毫升。炎性液体中的平均最大浓度在给药后3.8小时时为1.3微克/毫升。克林沙星在血浆中的平均消除半衰期为5.65小时。通过测定浓度-时间曲线下面积的比值评估，其进入炎性液体的总体渗透率为93.1%。给药后24小时，尿液中克林沙星的回收率为58.8%，48小时时为71.8%。
相似文献
1
Pharmacokinetics and inflammatory fluid penetration of clinafloxacin.克林沙星的药代动力学和炎性液体渗透情况
Antimicrob Agents Chemother. 1998 Feb;42(2):428-30. doi: 10.1128/AAC.42.2.428.
2
A study to determine the pharmacokinetics and inflammatory fluid penetration of gatifloxacin following a single oral dose.
J Antimicrob Chemother. 1999 Nov;44(5):701-4. doi: 10.1093/jac/44.5.701.
3
Single-dose pharmacokinetics and penetration of BMS 284756 into an inflammatory exudate.BMS 284756的单剂量药代动力学及在炎性渗出液中的渗透情况。
Antimicrob Agents Chemother. 2002 Jan;46(1):242-4. doi: 10.1128/AAC.46.1.242-244.2002.
4
The tolerance and pharmacokinetics of clinafloxacin (CI-960) in healthy subjects.健康受试者中克林沙星（CI-960）的耐受性和药代动力学
J Antimicrob Chemother. 1996 Dec;38(6):1023-9. doi: 10.1093/jac/38.6.1023.
5
Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219).曲伐沙星（CP-99,219）的药代动力学及在炎性液中的渗透情况
Antimicrob Agents Chemother. 1996 Jan;40(1):47-9. doi: 10.1128/AAC.40.1.47.
6
Pharmacokinetics and tissue penetration of the new fluoroquinolone grepafloxacin.新型氟喹诺酮类药物格帕沙星的药代动力学及组织穿透性
Antimicrob Agents Chemother. 1995 Feb;39(2):513-5. doi: 10.1128/AAC.39.2.513.
7
Pharmacokinetics and inflammatory fluid penetration of sparfloxacin.司帕沙星的药代动力学及炎性液体渗透情况
Antimicrob Agents Chemother. 1992 Nov;36(11):2444-6. doi: 10.1128/AAC.36.11.2444.
8
Pharmacokinetics and tissue penetration of gemifloxacin following a single oral dose.单次口服吉米沙星后的药代动力学及组织穿透性
J Antimicrob Chemother. 2001 Apr;47(4):431-4. doi: 10.1093/jac/47.4.431.
9
Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.司帕沙星的药代动力学及其与西沙必利和硫糖铝的相互作用。
Antimicrob Agents Chemother. 1997 Aug;41(8):1668-72. doi: 10.1128/AAC.41.8.1668.
10
Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration.口服或静脉注射后莫西沙星的药代动力学及炎性液渗透情况。
Antimicrob Agents Chemother. 1999 Jun;43(6):1508-10. doi: 10.1128/AAC.43.6.1508.
引用本文的文献
1
Relationship of quantitative structure and pharmacokinetics in fluoroquinolone antibacterials.氟喹诺酮类抗菌药物的定量结构与药代动力学的关系。
World J Gastroenterol. 2007 May 7;13(17):2496-503. doi: 10.3748/wjg.v13.i17.2496.
2
A critical review of the fluoroquinolones: focus on respiratory infections.氟喹诺酮类药物的批判性综述：聚焦于呼吸道感染
Drugs. 2002;62(1):13-59. doi: 10.2165/00003495-200262010-00002.
3
Pharmacokinetics of clinafloxacin after single and multiple doses.克林沙星单剂量和多剂量给药后的药代动力学
Antimicrob Agents Chemother. 2001 Sep;45(9):2529-35. doi: 10.1128/AAC.45.9.2529-2535.2001.
4
Clinafloxacin versus piperacillin-tazobactam in treatment of patients with severe skin and soft tissue infections.克林沙星与哌拉西林-他唑巴坦治疗重症皮肤及软组织感染患者的疗效比较
Antimicrob Agents Chemother. 2001 Feb;45(2):525-31. doi: 10.1128/AAC.45.2.525-531.2001.
5
Comparative in vitro activities of clinafloxacin and trovafloxacin against 1,000 isolates of bacteroides fragilis group: effect of the medium on test results.克林沙星与曲伐沙星对1000株脆弱拟杆菌属菌株的体外活性比较：培养基对试验结果的影响
Antimicrob Agents Chemother. 2000 Jun;44(6):1710-2. doi: 10.1128/AAC.44.6.1710-1712.2000.
6
Pharmacokinetics and pharmacodynamics of levofloxacin against Streptococcus pneumoniae and Staphylococcus aureus in human skin blister fluid.左氧氟沙星在人皮肤水疱液中对肺炎链球菌和金黄色葡萄球菌的药代动力学和药效学
Antimicrob Agents Chemother. 2000 May;44(5):1352-5. doi: 10.1128/AAC.44.5.1352-1355.2000.
7
Pharmacokinetics and pharmacodynamics of fluoroquinolones.氟喹诺酮类药物的药代动力学和药效学
Drugs. 1999;58 Suppl 2:29-36. doi: 10.2165/00003495-199958002-00006.
8
In vitro activities of clinafloxacin against contemporary clinical bacterial isolates from 10 North American centers.克林沙星对来自北美10个中心的当代临床分离菌株的体外活性。
Antimicrob Agents Chemother. 1998 May;42(5):1274-7. doi: 10.1128/AAC.42.5.1274.
本文引用的文献
1
The tolerance and pharmacokinetics of clinafloxacin (CI-960) in healthy subjects.健康受试者中克林沙星（CI-960）的耐受性和药代动力学
J Antimicrob Chemother. 1996 Dec;38(6):1023-9. doi: 10.1093/jac/38.6.1023.
2
Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219).曲伐沙星（CP-99,219）的药代动力学及在炎性液中的渗透情况
Antimicrob Agents Chemother. 1996 Jan;40(1):47-9. doi: 10.1128/AAC.40.1.47.
3
The in-vitro activity of CP 99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents.新型萘啶酮类抗菌剂CP 99,219的体外活性：与氟喹诺酮类药物的比较。
J Antimicrob Chemother. 1995 Jun;35(6):869-76. doi: 10.1093/jac/35.6.869.
4
The influence of protein binding upon tissue fluid levels of six beta-lactam antibiotics.蛋白质结合对六种β-内酰胺类抗生素组织液水平的影响。
J Infect Dis. 1980 Jul;142(1):77-82. doi: 10.1093/infdis/142.1.77.
5
Simplified, accurate method for antibiotic assay of clinical specimens.临床标本抗生素检测的简化、准确方法。
Appl Microbiol. 1966 Mar;14(2):170-7. doi: 10.1128/am.14.2.170-177.1966.
6
Pharmacokinetics and tissue penetration of orally administered lomefloxacin.口服洛美沙星的药代动力学和组织穿透性。
Antimicrob Agents Chemother. 1988 Oct;32(10):1508-10. doi: 10.1128/AAC.32.10.1508.
7
Comparative in vitro activity of PD 127,391, a new fluorinated 4-quinolone derivative.新型氟化4-喹诺酮衍生物PD 127,391的体外活性比较
Antimicrob Agents Chemother. 1988 Aug;32(8):1278-81. doi: 10.1128/AAC.32.8.1278.
8
In vitro activity of PD 127,391, an enhanced-spectrum quinolone.广谱喹诺酮类药物PD 127,391的体外活性
Antimicrob Agents Chemother. 1988 Aug;32(8):1251-6. doi: 10.1128/AAC.32.8.1251.
9
Pharmacokinetics and inflammatory fluid penetration of sparfloxacin.司帕沙星的药代动力学及炎性液体渗透情况
Antimicrob Agents Chemother. 1992 Nov;36(11):2444-6. doi: 10.1128/AAC.36.11.2444.
Zotero 插件